Central Veterinary Institute (CVI) of Wageningen UR
8221 RA Lelystad
Facilities of CVI in Lelystad include extensive laboratories and animal facilities allowing research on pathogens up on different containment levels, including BSL-(human)/BSL4(veterinary). The CVI acts as the National Reference Laboratory for animal infectious diseases and has extensive experience in diagnostics. In addition, CVI provides research on vaccines, novel diagnostics and associated products and acts as advisory body. Within Europe, CVI is a partner in various joint activities, such as Epizone and MedVetNet, and collaborates in a number of EU research projects.
The institute has expertise in genetics, genomics, microbiology, immunology, physiology, welfare and stress, animal health, nutrition, animal welfare, biomedical research and food safety. The institute in addition provides vaccines, diagnostics and associated products and gives advice with regard to issues regarding the animal production chain.
- Vector borne diseases
- Host pathogen interactions
- Avian Influenza
- Classical Swine Fever
Access contact person
Dr. Norbert Stockhofe-Zurwieden, DVM, Vet. Pathologist
Activities and services
CVI is equipped with excellent facilities designed to accommodate the entire range of (animal) experiments necessary to carry out research on breeding an genetics, functional genomics, infection biology, management, nutrition, product quality and veterinary and biomedical research.
It complies with ISO standards (9000:2001 and 17025) and GLP principles. With regard to genomic research, this includes ultra-high throughput DNA sequencing and marker analysis, micro-array facilities, high throughput 2D analysis, mass spectrometry and bioinformatics.
Facilities of CVI in Lelystad include extensive laboratories and animal facilities allowing research on pathogens up on different containment levels, including BSL-3(human)/BSL4(veterinary).
Description of the access to provide
CIV will carry out the experiments with emerging pathogens (provided that this is within our licence and the relevant expertise is available within CVI) for potential users and to some extent provide physical access to its facilities during crucial periods of the running experiments. While trained and experienced staff will carry out the standard procedures and the general maintenance, the external user might be on-site during sampling periods or other relevant procedures.
>> An access unit:
Access to animal room with 12 piglets up to 40 kg weight (or a equivalent of those in case of an other species) for 1 month including preparation and cleaning = effective appr. 25 days experiment.
Including feed and basic animal handling – caretaking; excluding specialized techniques and samplings.
>> Support offered under this proposal
CVI offers to the Infrastructure programme access to carry out trials with infectious pathogens in animals. The access will comprise the use of animal units, purchase of animals and their housing and care and biotechnical expertise. Material taken will be suitably preserved but not analyzed. Laboratory analyses of samples produced by the experiments are not included in this access and might be performed at extra cost in high security laboratory buildings.
Scientific support will include advice on experimental design and methodology, documentation of results for all experiments conducted during the project and appropriate sampling and conservation of samples. Removing samples and tissues out of BSL 3 facility is strictly limited and only possible by controlled exit.
The shipping of material that may possibly be infected by HC agents or which may contain nucleic acids of such agents must be carried out in accordance with the OIE Animal Health Code “IMPORTATION OF ANIMAL PATHOGENS.”
>> Outreach of new users
Potential new users will be informed about the access possibilities through calls for proposals targeting a specialized scientific audience. The calls will be published in a range of scientific journals specialsed in animal infectious disease research, together with guidelines on how to apply.
N° of access to provide: 10
Number of participants accepted
An average of two persons from each project are expected to participate to the initiation and termination of each experiment.
Travel and subsistence costs covered per participant
Based upon real costs for two persons during 2 x 5 consecutive days, not included in the “Unit costs”
Conditions of candidate involvement
Due to the unification of Europe, researchers can adjourn freely. Foreign researchers in the Netherlands are reviewed to the Dutch applicable standards. This takes place by means of comparison of curriculum vitae. It may be expected that at European level, agreements will be made about the competence of researchers, who perform animal research. It is to be expected that protocols for animal experiments from foreign researchers must be authorized by a national (authorized) researcher
After the end of each project the candidate will:
- Submit a short report
- Fill a questionnaire available on-line at: http://cordis.europa.eu/fp7/capacities/questionnaire_en.html
- The participant is entitled to publish the results of its work at the infrastructure in the open literature.All publications resulting from the project should acknowledge this EC-support by mentioning : “The research leading to these results has received funding from the European Community‘s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 228394”
- Proprietary research (research where results are not generally available to the public or only made available under confidentiality arrangements) cannot be supported.
- Travel and subsistence expenses linked to the access will be reimbursed upon approval of the report. Reimbursements will be done according to administrative rules of each hosting organisation.
- For more information about transnational access conditions, see the ANNEX III to the Grant Agreement - Infrastructures
Infrastructure ethical rules
All procedures with respect to animal experiments will be cleared by the Ethical Review Committee of the CVI and by the Veterinary Authorities in compliance with national laws and regulations.
- Jamal, S.M.; Bouma, A.; Broek, J. van den; Stegeman, J.A.; Chenard, G.; Dekker, A. (2008). Foot-and-mouth disease vaccine potency testing: the influence of serotype, type of adjuvant, valency, fractionation method, and virus culture on the dose-response curve in cattle. Vaccine 26 (50). - p. 6317 - 6321.
- Orsel, K.; Dekker, A.; Bouma, A.; Stegeman, J.; Jong, M.C. de (2008). Quantification of Foot and Mouth Disease Virus Excretion and Transmission within Groups of Lambs with and without Vaccination. In: Proceedings of the XXV Jubilee World Buiatrics Congress, 6 - 11 July, 2008, Budapest, Hungary. -
- Orsel, K.; Jong, M.C.M. de; Bouma, A.; Stegeman, J.A.; Dekker, A. (2008). The quantification of FMDV transmission in groups of vaccinated and non-vaccinated dairy cows. In: ISVEE, Cairns Australia, 6 -11 August 2006. -
- Orsel, K.; Dekker, A.; Bouma, A.; Stegeman, J.A.; Jong, M.C.M. de (2007). Quantification of foot and mouth disease virus excretion and transmission within groups of lambs with and without vaccination. Vaccine 25 (14). - p. 2673 - 2679.
- Orsel, K.; Dekker, A.; Bouma, A.; Stegeman, J.A.; Jong, M.C.M. de (2008). Difference in virus excretion between dairy cows and calves in the course of acute FMDV infection. In: ISVEE, Cairns Australia, 6 -11 August 2006. -
- Orsel, K.; Jong, M. de; Bouma, A.; Stegeman, J.A.; Dekker, A. (2008). FMDV transmission in calves and cows: same strain, same species, still different. In: VEEC-meeting (Dutch Society of Veterinary Epidemiology and Economy) Lelystad, The Netherlands,16 February 2006. -
- Weesendorp, E.; Stegeman, J.A.; Loeffen, W.L.A. (2008). Quantification of classical swine fever virus in aerosols originating from pigs infected with strains of high, moderate or low virulence. Veterinary Microbiology 135 (3-4). - p. 222 - 230.
- Weesendorp, E.; Stegeman, A.; Loeffen, W.L.A. (2008). Survival of classical swine fever virus at various temperatures in faeces and urine derived from experimentally infected pigs. Veterinary Microbiology 132 (3-4). - p. 249 - 259.
- Backx, A.; Heutink, C.G.; Rooij, E.M.A. van; Rijn, P.A. van (2007). Experimental bluetongue virus serotype 8 infection in sheep, goats and cows: A depiction of observed clinical signs. Lublin/Pulawy, Poland : First annual meeting Network of Excellence for Epizootic Disease Diagnosis and Control (EPIZONE), 2007-05-29/ 2007-06-01
- Eble, P.L.; Koeijer, A.A. de; Bouma, A.; Stegeman, J.A.; Dekker, A. (2006). Quantification of within- and between-pen transmission of Fouth-and-Mouth disease virus in pigs. Veterinary Research 37 (5). - p. 647 - 654.
- Wieringa-Jelsma, H.; Quak, J.; Loeffen, W.L.A. (2006). Limited BVDV transmission and full protection against CSFV transmission in pigs experimentally infected with BVDV type 1b. Veterinary Microbiology 118 (1-2). - p. 26 - 36.
- Goot, J. van der; Koch, G.; Jong, M.C.M. de; Boven, R.M. van (2005). Transmission experiments to study the effect of vaccination against H7N7 avian influenza virus in poultry. In: Abstracts of the society for Veterinary Epidemiology and Economics. - Utrecht : Veterinary Epidemiology and Economics (VEEC 17)
- Van der Goot JA, van Boven M, Stegeman A, van de Water SG, de Jong MC, Koch G. Transmission of highly pathogenic avian influenza H5N1 virus in Pekin ducks is significantly reduced by a genetically distant H5N2 vaccine. Virology. 2008, 382(1):91-7.
- Jeanet A. van der Goot, Michiel van Boven, Arjan Stegeman, Sandra G.P. van de Water, Mart C.M de Jong, and Guus Koch. The Effect of Vaccination on Transmission of Highly Pathogenic Avian Influenza H5N1 Virus in Peking Ducks, Vaccine, in press
- Eblé PL, Weerdmeester, K, van Hemert-Kluitenberg, F, Dekker, A. 2009. Intradermal vaccination of pigs against FMD with 1/10 dose results in comparable vaccine efficacy as intramuscular vaccination with a full dose. Vaccine 27: 1272-1278.
- Maas R, Tacken M, van Zoelen D, Oei H. Dose response effects of avian influenza (H7N7) vaccination of chickens: serology, clinical protection and reduction of virus excretion. Vaccine (2009) 27:3592-3597.
- Backx, A., Heutink, R., van Rooij, E.M.A., van Rijn, P.A.Transplacental and oral transmission of wild-type bluetongue virus serotype 8 in cattle after experimental infection. Vet. Microbiol. 2009; 138: 235-243.
- Quantification of the effect of vaccination on transmission of avian influenza (H7N7) in chickens.. van der Goot JA, Koch G, de Jong MC, van Boven M; Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18141-6.
- R.A. Maas, S. Venema, H.L. Oei, J.M.A.Pol, I.J.T.M. Claassen, A.A.H.M. ter Huurne.Efficacy of inactivated infectious bursal disease (IBD) vaccines; comparison of serology with protection of progeny chickens against IBD- virus strains of vaying virulence. Avian Pathology (2001) 30: 355-364.
- R.A. Maas, M. Komen, M. van Diepen, H.L Oei, I.J.T.M. Claassen. Correlation of Haemagglutinin-Neuraminidase and Fusion protein content with protective antibody response after immunisation with inactivated Newcastle disease vaccines. Vaccine (2003) 21 (23) 3136-3141.
- R. Maas, S. Venema, A. Kant, H. Oei, I. Claassen. Quantification of infectious bursal disease viral proteins 2 and 3 in inactivated vaccines as indicator of serological response and measure of potency. Avian Pathology (2004) 33 (2) 126-132.
- R. Maas, M. Tacken, L. Ruuls, G. Koch, E. van Rooij, N. Stockhofe-Zurwieden. Avian Influenza (H5N1) susceptibility and receptors in dogs. Emerging Infectious Diseases (2007) 13 (8) 1219-1221.
- R. Maas, M. Tacken, D. van Zoelen, H. Oei. Dose response effects of Avian Influenza H7N7 vaccination in chickens: serology, clinical protection and reduction of virus excretion. Vaccine (2009) 27 (27):3592-3597.
- Infrastructure website: http://www.cvi.wur.nl